Clinical Trials Browser

Sarcoma, Alveolar Soft Part

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary

Carcinoma, Renal Cell

Carcinoma, Non-Small-Cell Lung, Thymoma, Small Cell Lung Carcinoma

Thymoma, Thymus Neoplasms

Adult Solid Neoplasm

Small Cell Lung Carcinoma

Carcinoma, Renal Cell

Carcinoma, Non-Small-Cell Lung

Carcinoma, Renal Cell

Ovarian Neoplasms

Endometrial Adenocarcinoma

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Carcinoma, Renal Cell

Astrocytoma, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Familial ependymoma, Astrocytoma, Oligodendroglioma

Uterine Cervical Neoplasms

Squamous Cell Carcinoma of Head and Neck

Multiple Myeloma

Mesothelioma, Malignant

Lymphoma, Large B-Cell, Diffuse

Leukemia, Lymphocytic, Chronic, B-Cell

Carcinoma, Renal Cell

Unspecified Adult Solid Tumor, Protocol Specific

Pancreatic Neoplasms

Central Nervous System Metastases

Pancreatic Neoplasms

Urinary Bladder Neoplasms

Clinical Trials

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery

Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies

Sunitinib for Advanced Thymus Cancer Following Earlier Treatment

Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy

Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer

Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer

Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer

Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors

Sunitinib in Treating Patients With Recurrent Malignant Gliomas

Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma

Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery

Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

Sunitinib in Treating Patients With Relapsed Multiple Myeloma

Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma

Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma

Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies

Bevacizumab and Sunitinib in Treating Patients With Solid Tumors

Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors

Sunitinib in Treating Young Patients With Refractory Solid Tumors

Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine

Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer